Sinovac Biotech Ltd (SVA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sinovac Biotech Ltd (SVA) has a cash flow conversion efficiency ratio of 0.012x as of December 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($146.01 Million) by net assets ($12.02 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Sinovac Biotech Ltd for the company's overall valuation and market capitalisation.
Sinovac Biotech Ltd - Cash Flow Conversion Efficiency Trend (2000–2025)
This chart illustrates how Sinovac Biotech Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sinovac Biotech Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sinovac Biotech Ltd ranked by their cash flow conversion efficiency. Explore SVA cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chongqing Wangbian Electric (Group) Corp. Ltd.
SHG:603191
|
N/A |
|
Stratasys Ltd
NASDAQ:SSYS
|
0.006x |
|
Chongqing QinAn M&E PLC
SHG:603758
|
0.030x |
|
Shanxi Huhua Group Co Ltd
SHE:003002
|
0.018x |
|
Annexon Inc
NASDAQ:ANNX
|
-0.229x |
|
New York Mortgage Trust Inc
NASDAQ:NYMT
|
0.028x |
|
Aeolus Tyre Co Ltd
SHG:600469
|
0.039x |
|
Song Da Urban & Industrial Zone Investment and Development JSC
VN:SJS
|
-0.118x |
Annual Cash Flow Conversion Efficiency for Sinovac Biotech Ltd (2000–2025)
The table below shows the annual cash flow conversion efficiency of Sinovac Biotech Ltd from 2000 to 2025. View SVA stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.40 Billion | $-510.49 Million | -0.080x | -1342.69% |
| 2024-12-31 | $10.29 Billion | $-56.89 Million | -0.006x | -162.68% |
| 2023-12-31 | $12.02 Billion | $106.02 Million | 0.009x | +114.54% |
| 2022-12-31 | $12.71 Billion | $-770.75 Million | -0.061x | -105.48% |
| 2021-12-31 | $13.88 Billion | $15.35 Billion | 1.106x | +158.56% |
| 2020-12-31 | $1.12 Billion | $479.31 Million | 0.428x | +285.70% |
| 2019-12-31 | $352.19 Million | $39.07 Million | 0.111x | +307.75% |
| 2018-12-31 | $291.93 Million | $7.94 Million | 0.027x | -94.10% |
| 2017-12-31 | $129.67 Million | $59.76 Million | 0.461x | +486.55% |
| 2016-12-31 | $129.67 Million | $-15.46 Million | -0.119x | -486.47% |
| 2015-12-31 | $136.50 Million | $4.21 Million | 0.031x | +143.17% |
| 2014-12-31 | $141.73 Million | $-10.13 Million | -0.071x | -284.07% |
| 2013-12-31 | $143.64 Million | $5.58 Million | 0.039x | +130.91% |
| 2012-12-31 | $129.44 Million | $-16.25 Million | -0.126x | -230.93% |
| 2011-12-31 | $145.30 Million | $13.94 Million | 0.096x | +199.25% |
| 2010-12-31 | $147.76 Million | $-14.28 Million | -0.097x | -116.86% |
| 2009-12-31 | $84.47 Million | $48.41 Million | 0.573x | +192.64% |
| 2008-12-31 | $53.64 Million | $10.50 Million | 0.196x | +49.30% |
| 2007-12-31 | $32.90 Million | $4.32 Million | 0.131x | +270.93% |
| 2006-12-31 | $21.31 Million | $-1.64 Million | -0.077x | -12.10% |
| 2005-12-31 | $16.51 Million | $-1.13 Million | -0.068x | +30.71% |
| 2004-12-31 | $15.56 Million | $-1.54 Million | -0.099x | +37.57% |
| 2003-12-31 | $10.89 Million | $-1.72 Million | -0.158x | +72.89% |
| 2002-12-31 | $99.44K | $-58.05K | -0.584x | -180.57% |
| 2001-12-31 | $-682.96K | $-494.80K | 0.724x | 0.00% |
| 2000-12-31 | $-682.96K | $-494.80K | 0.724x | -- |
About Sinovac Biotech Ltd
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza;… Read more